CalciMedica, Inc.
CalciMedica, Inc. is a clinical-stage biopharmaceutical company developing therapies for serious inflammatory and immunologic diseases driven by calcium signaling and direct cellular injury. Its core scientific focus is inhibition of calcium release-activated calcium, or CRAC, channels, which the company believes could create a new class of therapeutics. The lead program is Auxora, an intravenously formulated small-molecule CRAC channel inhibitor containing zegocractin, which has been studied in acute critical care settings such as acute pancreatitis, severe COVID-19 pneumonia, pediatric asparaginase-induced pancreatic toxicity, and acute kidney injury with acute hypoxemic respiratory failure. The company is still in development mode, has no approved products, and is working toward a potential pivotal program in acute pancreatitis while relying on external capital and contract manufacturers.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaAuxora is the company's lead IV small-molecule CRAC channel inhibitor being developed for acute inflammatory and tissue-injury settings.
The platform includes discovery and development of therapies that modulate CRAC channel signaling across multiple indications.
This includes Phase 2 and planned pivotal clinical work in acute pancreatitis and other critical care indications.
Earlier-stage work supporting new indications and mechanism validation for CRAC inhibition.
Asiakkaat
CalciMedica does not yet have commercial customers because it has no approved products or product sales. Its current 'customers' are primarily clinical trial investigators, hospitals, and research sites that enroll patients in its studies, along with regulators such as the FDA that determine whether its programs can advance. If Auxora or another candidate is approved, the eventual buyers would likely be hospitals, critical care physicians, and health systems treating acute inflammatory conditions. The company may also pursue collaboration partners in the pharmaceutical industry to help fund development or support future commercialization.
Hospitals and research centers that run Auxora trials and generate the clinical data needed for regulatory advancement.
The FDA and other regulators that review trial design, safety, and efficacy before any commercialization can occur.
If approved, hospitals and health systems would buy Auxora for acute care use in serious inflammatory conditions.
Potential partners that may provide funding, development support, or commercialization capabilities.
Strategia
The company’s near-term strategy is to advance Auxora in acute pancreatitis and finalize the design of a potential pivotal program with the FDA in the first half of 2026. Because it has no commercial infrastructure, CalciMedica is focused on clinical development, regulatory alignment, and preserving capital rather than building a sales force today. It expects to continue relying on third-party manufacturers and may consider collaborations with larger pharmaceutical companies to strengthen development and future commercialization capabilities. The company also needs to secure substantial additional financing to fund ongoing trials, regulatory work, and eventual commercialization if approval is achieved.
A clear FDA-aligned pivotal path is necessary to move Auxora from Phase 2 evidence toward potential approval.
The company states current cash is insufficient to fund development through approval, making capital access essential.
Collaborations could provide non-dilutive funding, development expertise, and future commercialization support.
Maantiede
CalciMedica is headquartered in La Jolla, California, and its operations are centered in the United States. The company’s development work depends on U.S.-based management, regulatory engagement, and clinical trial execution, although future trials or collaborations could extend into other regions. Manufacturing is outsourced to contract manufacturing organizations rather than owned facilities, so geography matters mainly through the location and resilience of third-party suppliers and clinical sites. The company also highlights exposure to global health, geopolitical, tariff, and trade-related disruptions that could affect trials, collaborators, and supply chains.
Riskit
CalciMedica faces the classic risks of a clinical-stage biotech: it has no product revenue, a limited operating history, and a high probability of continued losses until a product is approved. Its lead asset, Auxora, still depends on clinical success and regulatory acceptance in acute pancreatitis, so any safety, efficacy, or trial-design setback could materially delay or end the program. The company also depends on external capital, and management has disclosed substantial doubt about its ability to continue as a going concern, which makes financing risk especially important. More broadly, competition from better-funded drug developers, dependence on third-party manufacturers and clinical sites, and supply-chain or geopolitical disruptions could all impair development timelines and increase costs.
- Clinical development failure for AuxoraVaikutus: KriittinenTodennäköisyys: Korkea
The company’s value is concentrated in a single lead asset that must prove safety and efficacy in pivotal studies.
Kohdistuu: Lead program in acute pancreatitis and other critical care indications
- Going-concern and financing riskVaikutus: KriittinenTodennäköisyys: Korkea
Management disclosed that current cash may not fund operations for the next year and that substantial additional capital is required.
Kohdistuu: All R&D and corporate operations
- Regulatory riskVaikutus: KorkeaTodennäköisyys: Korkea
The FDA may require additional data, different endpoints, or larger trials before approval can be pursued.
Kohdistuu: Pivotal program design and approval pathway
- Third-party manufacturing and trial execution riskVaikutus: KorkeaTodennäköisyys: Korkea
The company relies on CMOs and external research organizations rather than owning manufacturing or trial infrastructure.
Kohdistuu - Competitive riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Other companies may develop more effective, safer, or faster-to-market treatments for the same indications.
Kohdistuu: Acute pancreatitis and critical care markets
Kirjanpito
Harkinnanvaraiset erätClinical, preclinical, manufacturing, and consultant costs are recognized based on estimates and timing of vendor invoices.
Vaikutus: Can materially shift quarterly operating loss and liabilities
Management states current cash may not be sufficient to fund operations for one year, requiring disclosure and judgment.
Vaikutus: Affects investor assessment of liquidity and solvency
As a development-stage public company, equity awards are likely a meaningful non-cash expense.
Vaikutus: Impacts reported losses and dilution analysis
The company has used loans, ATM sales, and prior equity financings to fund operations.
Vaikutus: Affects cash flow, dilution, and financing-related expenses
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Acurx Pharmaceuticals, Inc.
ACXP · Pharmaceutical Preparations
Pacira BioSciences, Inc.
PCRX · Pharmaceutical Preparations
Pacira BioSciences is a U.S.-based biopharmaceutical company focused on non-opioid pain management products.
Immix Biopharma, Inc.
IMMX · Pharmaceutical Preparations
Nuvectis Pharma, Inc.
NVCT · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd
CNTB · Pharmaceutical Preparations
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company focused on developing rademikibart, an antibody designed to target IL-4Rα for asthma and COPD.
Biomerica, Inc
BMRA · In Vitro & In Vivo Diagnostic Substances
Päivitetty: 24.9.2026